scholarly journals POS-812 PLASMA OXALIC ACID AS A SIGNIFICANT RISK FACTOR FOR CARDIOVASCULAR DISEASE IN END-STAGE RENAL DISEASE PATIENTS

2021 ◽  
Vol 6 (4) ◽  
pp. S352-S353
Author(s):  
N. Stepanova MD ◽  
L. Snisar ◽  
L. Lebid
Keyword(s):  
Cardiovascular Disease ◽  
Risk Factor ◽  
Oxalic Acid ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Significant Risk ◽  
Significant Risk Factor ◽  
Stage Renal Disease ◽  
End Stage

Proteinuria and decreased body mass index as a significant risk factor in developing end-stage renal disease

2008 ◽  
Vol 12 (5) ◽  
pp. 363-369 ◽  
Author(s):  
Kunitoshi Iseki ◽  
Kaori Tokashiki ◽  
Chiho Iseki ◽  
Kentaro Kohagura ◽  
Kozen Kinjo ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Risk Factor ◽  
Renal Disease ◽  
Body Mass ◽  
End Stage Renal Disease ◽  
Significant Risk ◽  
Significant Risk Factor ◽  
Stage Renal Disease ◽  
End Stage

Assessing Plasma Total Homocysteine in Patients with End-Stage Renal Disease

2007 ◽  
Vol 27 (5) ◽  
pp. 476-488 ◽  
Author(s):  
Bradley L. Urquhart ◽  
Andrew A. House
Keyword(s):  
Cardiovascular Disease ◽  
Risk Factor ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Elevated Plasma ◽  
Plasma Thcy ◽  
Total Homocysteine ◽  
Stage Renal Disease ◽  
End Stage ◽  
Plasma Total Homocysteine

Elevated plasma total homocysteine (tHcy) is a risk factor for cardiovascular disease; however, in light of several recent randomized trials, the issue of causality has been cast into doubt. Patients with end-stage renal disease are particularly interesting as they consistently have elevated tHcy and their leading causes of morbidity and mortality are related to cardiovascular disease. In the present article, we review the early evidence for the homocysteine theory of atherosclerosis, homocysteine metabolism, mechanisms of toxicity, and pertinent available clinical investigations. Where appropriate, the sparse evidence of homocysteine in peritoneal dialysis is reviewed. We conclude by addressing the difficulties associated with lowering plasma tHcy in patients with end-stage renal disease and suggest some novel methods for lowering tHcy in this resistant population. Finally, to address the issue of causality, we recommend that clinicians and scientists await the results of the FAVORIT trial before abandoning homocysteine as a modifiable risk factor for cardiovascular disease, as this study has recruited patients from a population with consistently elevated plasma tHcy who are known to respond to vitamin therapy.

scholarly journals Obesity, End-stage Renal Disease, and Survival in an Elderly Cohort With Cardiovascular Disease

Obesity ◽  
2009 ◽  
Vol 17 (12) ◽  
pp. 2216-2222 ◽  
Author(s):  
Janice P. Lea ◽  
Daryl O. Crenshaw ◽  
Stephen J. Onufrak ◽  
Britt B. Newsome ◽  
William M. McClellan
Keyword(s):  
Cardiovascular Disease ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Elderly Cohort ◽  
Stage Renal Disease ◽  
End Stage

Atherogenic effect of plasma oxalic acid in end-stage renal disease patients

2021 ◽  
Vol 331 ◽  
pp. e109-e110
Author(s):  
N. Stepanova ◽  
L. Snisar ◽  
L. Lebid ◽  
S. Savchenko
Keyword(s):  
Oxalic Acid ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Stage Renal Disease ◽  
End Stage

Abstract 282: In Hospital Outcomes of Cardiac Arrest in Patient with End Stage Renal Disease

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_4) ◽  
Author(s):  
Muhammad Khan ◽  
Muhammad U Khan ◽  
Muhammad Munir
Keyword(s):  
Cardiac Arrest ◽  
Risk Factor ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
International Classification ◽  
International Classification Of Disease ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Background: End stage renal disease (ESRD) is a well-recognized risk factor for development of sudden cardiac arrest(SCA). There is limited data on outcomes after an in-hospital SCA event in ESRD patients. Methods: Data were obtained from National Inpatient Sample from January 2007 to December 2017. In-hospital SCA was identified using International Classification of Disease, 9th Revision, Clinical Modification, and International Classification of Disease, 10th Revision, Clinical Modification codes of 99.60, 99.63, and 5A12012. ESRD patients were subsequently identified using codes of 585.6 and N18.6. Propensity -matched analysis using logistic regression with SD caliper of 0.2 was used to match patients with and without ESRD. Crude and propensity-matched (PS) cohorts outcomes were calculated. Results: A total of 1,412,985 patients sustained in-hospital SCA during our study period. ESRD patients with in-hospital SCA were younger and had a higher burden of key co-morbidities. Mortality was similar in ESRD and non-ESRD patients in PS matched cohort (70.4% vs. 70.7%, p = 0.45, figure 1) with an overall downward trend over our study years (figure 2). Conclusion: In the context of in-hospital SCA, mortality is similar in ESRD and non-ESRD patients in adjusted analysis. Adequate risk factor modification could further mitigate the risk of in-hospital SCA among ESRD patients

Cardiovascular Disease as a Late Complication of End-Stage Renal Disease in Children

2005 ◽  
Vol 25 (3_suppl) ◽  
pp. 123-126 ◽  
Author(s):  
Jaap Groothoff ◽  
Mariken Gruppen ◽  
Eric De Groot ◽  
Martin Offringa
Keyword(s):  
Cardiovascular Disease ◽  
Aortic Valve ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Arterial Wall ◽  
Aortic Valve Calcification ◽  
Cross Sectional ◽  
Valve Calcification ◽  
Stage Renal Disease ◽  
End Stage

♦ Objective To analyze the late cardiovascular outcome of end-stage renal disease (ESRD) in children. ♦ Design A nation-wide long-term follow-up study. Determinants of outcomes and causes of death were retrospectively assessed. Patients underwent assessment of overall health state, B- and M-mode ultrasound of the carotid arteries, and echocardiography for cross-sectional analysis. ♦ Results We analyzed the medical course of all 249 adult Dutch patients with ESRD onset between 1972 and 1992 at age 0 – 14 years, and who were born before 1979. Of the 187 living patients, 140 participated in the cross-sectional part of the study. The standardized mortality rate was 31.0. Overall 5-, 10-, and 20-year survival after ESRD onset was 87%, 82%, and 78%, respectively. Cardiovascular disease accounted for most deaths (41%). In the whole group, left ventricular hypertrophy (LVH), aortic valve calcification, and arterial wall stiffening were highly prevalent. LVH was associated with hypertension at time of assessment. Aortic valve calcification was strongly associated with a long total duration of peritoneal dialysis (β = 0.33, p < 0.001). Arterial wall pathology was not associated with current treatment modality. ♦ Conclusions As in adults, cardiovascular disease is the most important cause of death in children with ESRD. Stricter reduction of volume overload, prevention of high serum calcium–phosphate product, and more vigorous treatment of hypertension are important targets to improve cardiovascular survival in children with ESRD.

Sign in / Sign up

Export Citation Format

Share Document